SCHEMBL2358812

SCHEMBL2358812

CC(C)(NC(=O)Nc1ccc2c(c1)OCCCO2)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.46
MAPT P10636 6/20 0.45
RORC P51449 1/20 0.42
PLTP P55058 3/20 0.42
LMNA P02545 2/20 0.41
DHODH Q02127 1/20 0.41
SMN1; SMN2 Q16637 8/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 1/20 0.41
ALDH1A1 P00352 2/20 0.40
PRNP P04156 1/20 0.40
POLB P06746 1/20 0.40
DGAT1 O75907 1/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
GSK3B P49841 1/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360023 0.97 TRPV1 (0.49) TRPV1MAPTRORCPLTPLMNA
SCHEMBL2315616 0.84 PLTP (0.51) MAPTRORCPLTPLMNASMN1; SMN2
SCHEMBL2315607 0.81 SMN1; SMN2 (0.52) MAPTRORCPLTPLMNASMN1; SMN2
SCHEMBL2316339 0.81 RORC (0.47) MAPTRORCPLTPLMNADHODH
SCHEMBL2317569 0.80 AR (0.52) MAPTRORCPLTPLMNADHODH
SCHEMBL2317084 0.80 MAPT (0.45) MAPTRORCPLTPLMNAMEN1
SCHEMBL2315078 0.80 DHODH (0.49) TRPV1MAPTRORCPLTPDHODH
SCHEMBL2318318 0.79 FPR2 (0.46) MAPTRORCPLTPMEN1KMT2A
SCHEMBL2315470 0.79 SAE1 (0.51) RORCMEN1KMT2APOLBDGAT1
SCHEMBL2316628 0.78 RORC (0.48) MAPTRORCPLTPSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 TRPV1 2529/4885MAPT 1671/4885RORC 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.